Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial

Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial

Background: Lacunar stroke, a frequent clinical manifestation of small vessel disease (SVD), differs pathologically from other ischaemic stroke subtypes and has no specific long-term secondary prevention. Licenced drugs, isosorbide mononitrate (ISMN) and cilostazol, have relevant actions to prevent...

Full description

Bibliographic Details
Main Authors: Gordon W. Blair, Jason P. Appleton, Katie Flaherty, Fergus Doubal, Nikola Sprigg, Richard Dooley, Carla Richardson, Iona Hamilton, Zhe Kang Law, Yulu Shi, Michael S. Stringer, Michael J. Thrippleton, Julia Boyd, Kirsten Shuler, Philip M. Bath, Joanna M. Wardlaw
Format: Article
Language:English
Published: Elsevier 2019-05-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537019300586

Internet

http://www.sciencedirect.com/science/article/pii/S2589537019300586

Similar Items